Los Angeles Capital Management LLC Purchases 131,934 Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX)

Los Angeles Capital Management LLC raised its position in Pacira BioSciences, Inc. (NASDAQ:PCRX) by 942.7% during the 3rd quarter, according to its most recent filing with the SEC. The institutional investor owned 145,930 shares of the company’s stock after acquiring an additional 131,934 shares during the period. Los Angeles Capital Management LLC’s holdings in Pacira BioSciences were worth $2,196,000 as of its most recent filing with the SEC.

A number of other large investors have also recently bought and sold shares of PCRX. Vanguard Group Inc. lifted its position in shares of Pacira BioSciences by 0.3% in the first quarter. Vanguard Group Inc. now owns 5,113,384 shares of the company’s stock worth $149,413,000 after purchasing an additional 14,960 shares in the last quarter. Pacer Advisors Inc. boosted its stake in shares of Pacira BioSciences by 37.5% during the 2nd quarter. Pacer Advisors Inc. now owns 2,162,787 shares of the company’s stock worth $61,877,000 after buying an additional 590,082 shares during the last quarter. Renaissance Technologies LLC grew its holdings in shares of Pacira BioSciences by 9.8% in the 2nd quarter. Renaissance Technologies LLC now owns 2,066,197 shares of the company’s stock valued at $59,114,000 after acquiring an additional 184,000 shares in the last quarter. Dimensional Fund Advisors LP increased its position in shares of Pacira BioSciences by 12.2% in the second quarter. Dimensional Fund Advisors LP now owns 1,828,065 shares of the company’s stock valued at $52,300,000 after acquiring an additional 198,936 shares during the last quarter. Finally, Clearbridge Investments LLC boosted its position in Pacira BioSciences by 2.3% during the first quarter. Clearbridge Investments LLC now owns 1,172,150 shares of the company’s stock valued at $34,250,000 after purchasing an additional 26,463 shares during the last quarter. Institutional investors and hedge funds own 99.73% of the company’s stock.

Pacira BioSciences Price Performance

Pacira BioSciences stock opened at $16.45 on Thursday. The company has a market capitalization of $759.55 million, a price-to-earnings ratio of -8.10 and a beta of 0.82. The stock’s 50 day moving average is $15.69 and its 200-day moving average is $20.81. The company has a current ratio of 2.25, a quick ratio of 1.89 and a debt-to-equity ratio of 0.51. Pacira BioSciences, Inc. has a 12 month low of $11.16 and a 12 month high of $35.95.

Wall Street Analyst Weigh In

Several research analysts have weighed in on PCRX shares. Piper Sandler lowered Pacira BioSciences from an “overweight” rating to a “neutral” rating and lowered their price target for the stock from $42.00 to $11.00 in a research report on Monday, August 12th. Jefferies Financial Group upped their price target on shares of Pacira BioSciences from $15.00 to $18.00 and gave the stock a “buy” rating in a research report on Tuesday, September 24th. Needham & Company LLC reissued a “buy” rating and issued a $22.00 price objective on shares of Pacira BioSciences in a research report on Friday, November 8th. Barclays dropped their target price on shares of Pacira BioSciences from $25.00 to $17.00 and set an “equal weight” rating on the stock in a report on Tuesday. Finally, JPMorgan Chase & Co. reiterated an “underweight” rating and set a $10.00 price target (down previously from $45.00) on shares of Pacira BioSciences in a report on Monday, August 12th. Two analysts have rated the stock with a sell rating, four have assigned a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $23.50.

Pacira BioSciences Company Profile

Pacira BioSciences, Inc engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves.